Medical oncologist specialising in melanoma, including adjuvant immunotherapy and targeted therapy trials. Chief of hematology-oncology at Penn and ASCO president for 2023-2024.
Role
ASCO President 2023-2024; Chief, Hematology-Oncology, University of Pennsylvania
Institution
Specialisms
MelanomaImmunotherapyProfessional leadership
| Title | Journal | Year |
|---|---|---|
| Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose? | Journal of Clinical Oncology | 2004 |
| A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group | Annals of Internal Medicine | 1996 |
Pages like this
not linked directly; found by shared links- InstitutionThe Wistar Institute
Shares Abramson Cancer Center, University of Pennsylvania, Melanoma.
- Key paperASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors
Shares American Society of Clinical Oncology (ASCO), Melanoma.
- InstitutionSociety of Surgical Oncology
Shares American Society of Clinical Oncology (ASCO), Melanoma.
- PathwayMicrobiome–tumour interactions
Shares Abramson Cancer Center, University of Pennsylvania, Melanoma.